GPS Wealth Strategies Group’s Sarepta Therapeutics SRPT Stock Holding History

GPS Wealth Strategies Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-176	Closed	-$27.8K	–	1437
2024 Q2	$27.8K	Hold	176	–	–	﹤0.01%	678
2024 Q1	$22.8K	Hold	176	–	–	﹤0.01%	692
2023 Q4	$17K	Sell	176 -169	-49%	-$16.2K	﹤0.01%	727
2023 Q3	$41.8K	Sell	345 -56	-14%	-$6.33K	0.01%	520
2023 Q2	$45.9K	Hold	401	–	–	0.01%	510
2023 Q1	$55.3K	Buy	+401	New	+$52K	0.01%	462
2022 Q4	–	Sell	-401	Closed	-$44K	–	955
2022 Q3	$44K	Hold	401	–	–	0.01%	456
2022 Q2	$30K	Sell	401 -33	-8%	-$2.43K	0.01%	543
2022 Q1	$34K	Sell	434 -40	-8%	-$3.06K	0.01%	493
2021 Q4	$43K	Hold	474	–	–	0.01%	434
2021 Q3	$44K	Buy	474 +21	+5%	+$1.62K	0.01%	412
2021 Q2	$35K	Buy	+453	New	+$34.3K	0.01%	489

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

GPS Wealth Strategies Group's SRPT Position: Q3 2024 in Review

GPS Wealth Strategies Group sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 176 shares — an estimated $27.8K sold.

GPS Wealth Strategies Group first reported a position in SRPT in Q2 2021 and held it in 12 quarters. The position peaked at $55.3K in Q1 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

GPS Wealth Strategies Group reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
GPS Wealth Strategies Group sold 176 Sarepta Therapeutics shares in Q3 2024, an estimated $27.8K.
GPS Wealth Strategies Group first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 12 quarters.
GPS Wealth Strategies Group's Sarepta Therapeutics position peaked at $55.3K in Q1 2023.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on GPS Wealth Strategies Group's 13F filing for Q3 2024, filed 29 Oct 2024.